ArticleEuropean journal of nuclear medicine and molecular imaging2026
The role of [⁶⁸Ga]Ga-FAP-2286 PET/CT in the evaluation of treatment response in gastrointestinal system malignancies.
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The value ofEuropean journal of nuclear medicine and molecular imaging · 2026Article
- The FAP-FDG Integration Score (FFIS): Development and prognostic validation of a dual-tracer PET phenotype for solid tumors.European journal of nuclear medicine and molecular imaging · 2026Article
- Colorectal Cancer: A Landscape of New Potential Radiopharmaceuticals.Molecular diagnosis & therapy · 2026Review
- [Breast cancer research : BCR · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate the potential efficacy of [⁶⁸Ga]Ga-FAP-2286 PET/CT in evaluating treatment response in patients with gastrointestinal system malignancies. MATERIALS AND
methodsPatients with histopathologically confirmed gastrointestinal malignancies who underwent [⁶⁸Ga]Ga-FAP-2286 PET/CT for treatment response assessment between November 2020 and January 2025 were included. All images were evaluated by three experienced nuclear medicine physicians. The maximum standardized uptake values (SUVmax), total tumor volumes, and total lesion FAP expression values of primary tumors and metastases were recorded. At the same time, serum tumor marker levels were analyzed. Imaging responses were assessed separately according to PERCIST criteria on [⁶⁸Ga]Ga-FAP-2286 PET/CT and RECIST criteria on CT. Survival outcomes were analyzed using the Kaplan-Meier method, and their association with treatment response on [⁶⁸Ga]Ga-FAP-2286 PET/CT was assessed using the Log-Rank (Mantel-Cox) test and Cox proportional hazards regression. A p-value < 0.05 was considered statistically significant in all analyses.
resultsA total of 100 [⁶⁸Ga]Ga-FAP-2286 PET/CT scans were performed in 50 patients (mean age: 61.62 ± 12.95), both before and after treatment. Among the included patients, 70% had gastric cancer, 14% had colon cancer, 8% had pancreatic cancer, 4% had appendiceal cancer, 2% had hepatocellular carcinoma (HCC), and 2% had cholangiocellular carcinoma. Primary/recurrent tumor lesions were observed in 62% of patients, lymph node metastases in 24%, visceral metastases in 10%, peritoneal metastases in 76%, and bone metastases in 14%. A strong correlation was found between tumor volumes and total lesion FAP expression measured by [⁶⁸Ga]Ga-FAP-2286 PET/CT and the corresponding serum tumor markers (Area Under the Curve [AUC] for delta tumor volume and total lesion FAP expression = 0.875). There was a statistically significant and near-perfect concordance between [⁶⁸Ga]Ga-FAP-2286 PET PERCIST and CT RECIST criteria (Kappa = 0.833, p < 0.05). Moderate agreement was found for primary tumors (Kappa = 0.526, p < 0.05) and bone metastases (Kappa = 0.657, p < 0.05), while excellent agreement was observed for lymph node (Kappa = 1.0, p < 0.05), peritoneal (Kappa = 0.815, p < 0.05), and visceral metastases (Kappa = 1.0, p < 0.05). According to the Kaplan-Meier analysis, treatment response assessed by [⁶⁸Ga]Ga-FAP-2286 PET/CT was predictive of overall survival (p = 0.02). Median overall survival was 7.6 months in patients with progressive disease and 19.8 months in those with stable disease, as defined by PERCIST criteria. Median survival was not reached in patients showing partial or complete response.
conclusionIn gastrointestinal system malignancies, a strong correlation was observed between serum tumor markers and both total tumor volumes and total lesion FAP expression values derived from [⁶⁸Ga]Ga-FAP-2286 PET imaging. Additionally, molecular response assessed by [⁶⁸Ga]Ga-FAP-2286 PET/CT was predictive of overall survival. [⁶⁸Ga]Ga-FAP-2286 PET/CT appears to be an effective tool for assessing treatment response and monitoring patients with gastrointestinal malignancies.
Indexed as
Identifiers
41023236What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.